## 123 Regid PCT/PTO 36 DEC 2005

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES ATTORNEY'S DOCKET NUMBER DESIGNATED/ELECTED OFFICE (DO/EO/US) **130-PCT-US CONCERNING A SUBMISSION UNDER 35 U.S.C. 371** 9675 CFR 1.5) INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/CA2004/000873 14 JUNE 2004 13 JUNE 2003 TITLE OF INVENTION Acylated and Non-Acylated Imidazo[2,1-b]-1,3,4,-Thiadiazole-2-Sulfonamides, and Uses Thereof APPLICANT(S) FOR DO/EO/US James B. Jaquith, John W. Gillard Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. Main This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items items (5), (6), (9) and (21) indicated below. The US has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is attached hereto (required only if not communicated by the International Bureau) b. has been communicated by the International Bureau c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

PTO-1390 (Rev. 07-2005)

## IAP9 Rec'd PCT/PTO 06 DEC 2003

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known see 37 CFR 1.5)  INTERNATIONAL APPLICATION NO.  PCT/CA2004/000873					ATTORNEY'S DOCKET NO.  130-PCT-US	
20. Other items or information:						
The follow	ving fees have	been submitted			CALCULATIONS	PTO USE ONLY
21. Basic National fee (37 CFR 1.492(a)) \$300.00					\$300.00	μ'
22.  Examination fee (37 CFR 1.492©) If the written opinion prepared by ISA/US or the international preliminary examination report						P
prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) \$0					\$200.00	
All other situations \$200.00					<u> </u>	
23. ⊠ Search fee (37 CFR 1.492(b)) If the written opinion prepared by ISA/US or the international preliminary examination report						
prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4) . \$0						
Search fee (37 CFR 1.445(a)(2) has been paid o the international application to the					\$500.00	
USPTO as an International Searching Authority \$100.00						
International Search Report prepared by an ISA other than the US and Provided to the						
office or previously communicated to the US by the IB						
\$400.00 All other situations \$500.00						
TOTAL OF 21,22 and 23					\$1000.00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding						
sequence listing in compliance with 37 CFR 1.821© or (e) or computer program listing in an						·
electronic medium) (37 CFR 1.492 (j)). The fee is \$250.00 for each additional 50 sheets of paper or fraction thereof.						•
Total Sheets	Extra Sheets	ra Sheets Number of each additional 50 or fraction RATE				
			thereof (round up to a whole number)			
-100=	50 =		X\$250			
Surcharge of \$130.00 for furnishing any of the search fee, examination fee or the oath or declaration						
after the date of commencement of the national stage (37 CFR 1.492(h))						
CLAIMS		NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims		45-20 =	25	X \$50.00	1250.00	
Independent Claims		4 - 3 =	1	X \$200.00	200.00	
		, ,	·	,		
MULTIPLE DEPENDENT CLAIMS (if applicable)  X \$360.00						
						<del></del>
TOTAL OF ABOVE CALCULATIONS =  Applicant claims small entity status See 37 CFR 1.27. Fees above are reduced y ½.					2450.00	
Applicant claims small entity status See 37 CFR 1.27. Fees above are reduced y 72.  SUBTOTAL =					1225.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from					1225.00	
the earliest claimed priority date (37 CFR 1.492(i)).						
TOTAL NATIONAL FEE =					1225.00	
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +						
TOTAL FEES ENCLOSED =					1225.00	
					Amount to be Refunded	\$
					Amount to be	
					Charged:	\$

10/559675 IAP9 Rec'd PCT/PTO 06 DEC 2005

Approved for use through 3/31/2007. OMB 0651-002

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. a. A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed. b. Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$\_\_\_\_ to cover the above fees. c. The Commissioner is hereby authorized o charge any additional fees which may be required, or credit any overpayment to Deposit Account No. A duplicate copy of this sheet is enclosed. d. X Fees are to be charged to a credit card. WARNING: In formation on this for may become public. Credit information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the International Application to pending status. Send all correspondence to: Philip A. Swain, Ph.D. c/o Aegera Therapeutics 810 Chemin du Golf Nun's Island, Quebec CANADA H3E 1A8 REGISTRATION NO: 55,978 Telephone: (514) 288 - 4091 Ext: 353 Fax: (514) 288 – 9280